Genetics may determine link between aspirin, colon cancer risk
the ONA take:
According to a new study published in the Journal of the American Medical Association (JAMA), researchers have found that a person's individual genetics may determine if a person will have a reduced risk of colon cancer from taking aspirin.
The association between taking aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) and colorectal cancer prevention is well known, but it is not understood why some people benefit from the agents and some do not.
Therefore, researchers from four countries sought to investigate whether there is an association between certain DNA variations and the protection that aspirin confers.
For the study, researchers analyzed the data of over 17,000 people from ten large studies. They identified 8,624 people who developed colorectal cancer and 8,553 people who did not.
Results showed that there was DNA evidence that 1 in 25 people do not benefit from aspirin. Researchers found that those people may actually have an increased risk of developing colorectal cancer if they take aspirin.
A person's individual genetics may determine if a person will have a reduced risk of colon cancer from taking aspirin.
Sign Up for Free e-newsletters
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer
- Better Postoperative Outcomes With RAMIE for Esophageal Cancer
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|